# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

> **NCT06563115** · PHASE1 · COMPLETED · sponsor: **EncuraGen, Inc** · enrollment: 64 (actual)

## Conditions studied

- Insulin Resistance

## Interventions

- **DRUG:** (PEG)-BHD1028 Single Ascending Dose
- **DRUG:** (PEG)-BHD1028 Multiple Ascending Dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06563115
- **Lead sponsor:** EncuraGen, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-18
- **Primary completion:** 2024-04-23
- **Final completion:** 2024-06-23
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563115, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06563115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*